Overview & Definition

- Primary cutaneous CD30+ T-cell lymphoproliferative disorders (LPDs) represent a spectrum that includes primary cutaneous ALCL, lymphomatoid papulosis, and "borderline" cases with overlapping clinical and histopathologic features.\(^{a,b}\)
- Clinical correlation with histopathologic features is essential for establishing the diagnosis of primary cutaneous CD30+ T-cell LPDs; diagnosis cannot be made based on pathology review alone.

Differential diagnosis

- It is critical to distinguish CD30+ T-cell LPDs from other CD30+ processes involving the skin that include:
  - Systemic lymphomas (eg, systemic ALCL, ATLL, PTCL),
  - Other cutaneous process such as other CD30+ skin lymphomas such as mycosis fungoides (MF), especially transformed MF, cytotoxic T-cell lymphomas, and
  - Benign disorders such as lymphomatoid drug reactions, arthropod bites, viral infections and others.
- Lymphomatoid drug reactions has been linked with certain drugs (eg, amlodipine, carbamazepine, cefuroxime, valsartan) and is associated with CD30+ atypical large cells in histology
- MF and primary cutaneous CD30+ T-cell LPD can coexist in the same patient.

Primary cutaneous ALCL (PC-ALCL)

- Represents about 8% of cutaneous lymphoma cases.\(^{b}\)
- Unlike systemic ALCL, PC-ALCL typically follows an indolent course and although cutaneous relapses are common an excellent prognosis is usually maintained.\(^{c}\)
- Histologically characterized by diffuse, cohesive sheets of large CD30-positive (in >75%) cells with anaplastic, pleomorphic, or immunoblastic appearance.\(^{a,b}\)
- Clinical features typically include solitary or localized nodules or tumors (often ulcerated); multifocal lesions occur in about 20% of cases. Extracutaneous disease occurs in about 10% of cases, usually involving regional lymph nodes.\(^{a,b}\)
- Except in rare cases, PC-ALCL is ALK-.

Lymphomatoid papulosis (LyP)

- LyP has been classified (WHO-EORTC) under lymphomas but may be best classified as a LPD as it is a uniformly spontaneously regressing process.\(^{b}\)
- LyP has been reported to be associated with other lymphomas such as MF, PC-ALCL, systemic ALCL, or Hodgkin lymphoma.\(^{d,e}\)
- Histologically heterogenous with large atypical anaplastic, immunoblastic, or Hodgkin-like cells in a marked inflammatory background; several histologic subtypes (types A to D, with CD30-positive cells) defined based on evolution of skin lesions.\(^{d}\)
- Clinical features characterized by chronic, recurrent spontaneously regressing papulonodular (grouped or generalized) skin lesions.\(^{a,b,d}\)

See Diagnosis (PCTLD-2)


\(^{e}\)Due to overlapping immunophenotype and morphology, need to use caution to \textit{not} diagnose CD30+ T-cell in lymph nodes as HL (Eberle FC, Song JY, Xi L, et al. Nodal involvement by cutaneous CD30-positive T-cell lymphoma mimicking classical Hodgkin lymphoma. Amer J Surg Pathol 2012;36:716-725.)
### DIAGNOSIS

**ESSENTIAL:**
- Clinical presentation: see Overview and Definition
- Clinical pathologic correlation is essential
- Complete skin examination for evidence of MF
- Biopsy of suspicious skin sites
  - Histopathology review of adequate biopsy (punch, incisional, excisional).
  - Review of all slides with at least one paraffin block representative of the tumor should be done by a pathologist with expertise in the diagnosis of cutaneous T-cell lymphoma. Rebiopsy if consult material is nondiagnostic.
- Adequate immunophenotyping to establish diagnosis on skin biopsy:
  - IHC: CD3, CD4, CD8, CD20, CD30, CD56, βF1, ALK1

**USEFUL UNDER CERTAIN CIRCUMSTANCES:**
- On skin biopsy:
  - Expanded IHC: CD2, CD5, CD7, CD25, TIA1, granzyme B, perforin, GM1, EBER-ISH
  - Molecular analysis to detect: gene rearrangements: TCR (assessment of clonality)
- Excisional or incisional biopsy of suspicious lymph nodes (in absence of definitive skin diagnosis)
- Assessment of HTLV-1 serology in at-risk populations to identify CD30+ ATLL

- Cutaneous anaplastic large cell lymphoma (ALCL)
- Lymphomatoid papulosis (LyP)

---

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
WORKUP

**ESSENTIAL:**
- Complete physical examination including entire skin; ^k palpation of peripheral lymph node regions; liver or spleen enlargement
- CBC, differential
- Comprehensive metabolic panel
- LDH
- Chest/abdominal/pelvic contrast-enhanced CT or integrated whole body PET-CT
- Biopsy suspicious nodes ^e, ^i, ^m

**USEFUL IN SELECTED CASES:**
- Pregnancy testing in women of child-bearing age ^n
- Bone marrow aspiration and biopsy optional for solitary C-ALCL or C-ALCL without extracutaneous involvement on imaging

**LyP**

**ESSENTIAL:**
- Complete physical examination including entire skin; ^k palpation of peripheral lymph node regions; liver or spleen enlargement
- CBC, differential
- Comprehensive metabolic panel
- LDH

**USEFUL IN SELECTED CASES:**
- Pregnancy testing in women of child-bearing age ^n
- Chest/abdominal/pelvic contrast-enhanced CT or integrated whole body PET-CT ^j, ^o
- Bone marrow aspiration and biopsy (not done for typical LyP) ^j, ^o

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
**NCCN Guidelines Version 1.2014**  
**Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders**

<table>
<thead>
<tr>
<th>SUBTYPE</th>
<th>EXTENT OF DISEASE</th>
<th>PRIMARY TREATMENT</th>
<th>FOLLOW-UP$^s$</th>
<th>RELAPSE/REFRACTORY DISEASE</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Solitary or grouped lesions</td>
<td>Surgical excision ± RT$^q$ or RT$^q$</td>
<td>Response → Observe for recurrence</td>
<td>• Retreat with initial treatment if disease confined to skin</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>No response/refractory</td>
<td>• For multifocal lesions or extracutaneous involvement, see below</td>
</tr>
<tr>
<td>Primary cutaneous ALCL$^p$</td>
<td>Multifocal lesions</td>
<td>Methotrexate (≤100 mg weekly) or RT$^q$ or Systemic retinoids$^r$ or Pralatrexate or Observation, if asymptomatic or Interferon alpha (category 2B)</td>
<td>Response$^t$ → Observe for recurrence</td>
<td>• Clinical trial</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>No response/refractory</td>
<td>• Treat with same (unless refractory or intolerant) regimen</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Alternative regimen not used for primary treatment</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Mycosis fungoides “Category C Systemic Therapies” (SYST-CAT C) (See MFSS-A)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Clinical trial</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Treat with same (unless refractory or intolerant) regimen</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Alternative regimen not used for primary treatment</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Mycosis fungoides “Category C Systemic Therapies” (SYST-CAT C) (See MFSS-A)</td>
</tr>
<tr>
<td>Cutaneous ALCL with regional node (excludes systemic ALCL)</td>
<td></td>
<td>Methotrexate ± RT$^q$ or Pralatrexate ± RT$^q$ or CHOP or CHOEP ± RT$^q$ in selected cases or RT$^q$ in selected cases</td>
<td>Response → Observe for recurrence</td>
<td>• Retreat with initial treatment if disease confined to skin</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>No response/refractory</td>
<td>• For multifocal lesions or extracutaneous involvement, see below</td>
</tr>
</tbody>
</table>

$^p$Regression of lesions may occur in up to 44% of cases.  
$^q$See Principles of Radiation Therapy (NHODG-D).  
$^r$Limited data from case reports (eg, bexarotene).  
$^s$Mycosis fungoides can develop over time; continue to conduct thorough skin exam during follow-up.  

$^t$Patients achieving a response and/or a clinical benefit with cutaneous disease should be considered for maintenance or taper regimens to optimize response duration. Patients who relapse often respond well to the same treatment. Patients with a PR should be treated with the other options in the primary treatment list to improve response before moving onto treatment for refractory disease. Patients with relapse or persistent disease after initial primary treatment may be candidates for clinical trials.

Note: All recommendations are category 2A unless otherwise indicated.  
Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
# NCCN Guidelines Version 1.2014
## Primary Cutaneous CD30+ T-Cell Lymphoproliferative Disorders

**SUBTYPE**

- Limited lesions or asymptomatic
- Extensive lesions or symptomatic

**EXTENT OF DISEASE**

- Observation (preferred for asymptomatic)
- Topical steroids
- Phototherapy

**PRIMARY TREATMENT**

- Observation (preferred for asymptomatic)
- Topical steroids
- Phototherapy
- Methotrexate [10-35 mg weekly]
- Systemic retinoids
- Topical steroids
- Topical nitrogen mustard

**FOLLOW-UP**

- Asymptomatic disease
- Symptomatic disease
- Response
- No response/refractory

**RELAPSE/REFRACTORY DISEASE**

- Continue observation or Topical steroids
- Treat with alternative regimen not used for primary treatment or Other regimens
- Clinical trial or Observation or Retreat or treat with alternative regimen not used for primary treatment

### Notes

- All recommendations are category 2A unless otherwise indicated.
- Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.
- Limited data from case reports (e.g., bexarotene).
- Life-long follow up is warranted due to high risks for second lymphoid malignancies; continue to conduct thorough skin exam during follow-up.

"Patients achieving a response and/or a clinical benefit may be considered for maintenance or taper regimens to optimize response duration. Patients who relapse often respond well to the same treatment. Patients with a PR should be treated with the other options in the primary treatment list to improve response before moving onto treatment for refractory disease. Patients with relapse or persistent disease after initial primary treatment may be candidates for clinical trials."